OTC · RVRC
Revium Recovery Inc.
$1.43$0.00 (0.0%)
Revium Recovery Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.37% below the high.
Loading market information…
OTC · SSYNF · USD
Stock price
Quote as of Jun 30, 2023, 07:36 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Sensyne Health plc, an Oxford, UK-headquartered company founded in 2018, is a prominent healthcare technology provider. It develops innovative software solutions that facilitate connections between medical practitioners and patients throughout the United Kingdom and the United States. The company’s diverse product portfolio encompasses digital tools for patient monitoring and management, diagnostic analysis, and advanced AI algorithms. Key offerings for patient care include web-based applications like CVm-Health for COVID-19 self-monitoring, DBm-Health for clinician-supervised diabetes management, and BPm-Health for pregnant women to self-monitor blood pressure. Prescribed digital therapeutics are also prominent, such as GDm-Health for remote gestational diabetes management, EDGE for at-home chronic obstructive pulmonary disease (COPD) monitoring, and Support-HF for remote heart failure monitoring. Beyond direct patient interfaces, Sensyne Health provides MagnifEye for reading and analyzing diagnostic tests, SEND as an evidence-based digital charting system for vital signs, and CleanSpace for tracking personal air pollution exposure. Its technological backbone includes the Sense clinical AI algorithm engine, alongside specialized algorithms like SYNE-COV for predicting COVID-19 patient outcomes and SYNE-OPS for real-time operational patient management. Sensyne Health actively collaborates with various organizations across the healthcare and research sectors. It maintains strategic research alliances with leading pharmaceutical firms such as Bayer and Roche. Further research collaborations include an agreement with Alexion to investigate patient prevalence and outcomes in specific disease areas, and a partnership with Bristol Myers Squibb focused on applying machine learning to rare blood disease research. Academic ties are evident through its research agreement with the University of Oxford for a multi-omics drug discovery project in asthma. Additionally, the company holds strategic research agreements with several NHS Trusts, including Milton Keynes University Hospital, Somerset, Hampshire, Royal Wolverhampton, and Royal Devon and Exeter.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:07 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
KEEP COMPARING
$1.43$0.00 (0.0%)
Revium Recovery Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.37% below the high.
$0.00$0.00 (0.0%)
Sangui Biotech International, Inc.’s quoted price sits in the lower half of its reported 52-week range, 86.67% below the high.
$0.00$0.00 (0.0%)
Neuropathix, Inc.: Healthcare · Biotechnology.
$0.00-$0.01 (-98.33%)
Total Brain Limited: Healthcare · Medical - Healthcare Information Services.
$0.00$0.00 (0.0%)
Humanigen, Inc.: Healthcare · Biotechnology.
$0.00$0.00 (0.0%)
Diagnocure, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
NMC Health plc’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
$0.00-$0.00 (0.0%)
MobileSmith, Inc.: Healthcare · Medical - Healthcare Information Services.
